There are a multitude of regulations that impact clinical research, and it’s vital to stay up to date on the latest industry developments. To get the latest information and insights on a broad spectrum of topics, Health Care Compliance Association®(HCCA®) invites you to join us for our 28th Annual Compliance Institute, April 14–17.
If there wasn’t already a general awareness among the personnel of the Penn State Cancer Institute Clinical Trials Office that February is National Cancer Prevention Month, you may guess the fact that breast cancer survivor Doris Shank, BSN, MSN, administrative director of the office, is preparing for her second cancer-related surgery soon has brought the topic of prevention to mind for some of them in any event.
When the ACRP Certified Professional (ACRP-CP®) certification launched in 2017, it made available to the clinical research field a rigorously developed and validated test leading to a credential highlighting the skills of professionals whose job roles do not easily stay within the boundaries of traditional clinical research coordinators (CRCs), clinical research associates (CRAs), or principal investigators.
Signed into law in August 2022, the IRA authorizes Medicare to negotiate directly with drug companies on prices. This process is viewed by many in the industry as “nothing more than price setting.” The CMS sent initial offers for the first 10 prescription drugs selected for negotiation on February 1, 2024.
This will be a critical year for professionals throughout the clinical research enterprise to build on the momentum gained in 2023 for improving diversity, equity, and inclusion (DEI)—not just among the volunteer participants in clinical trials, but also among all other stakeholders in their design, management, and results.